Provided by Tiger Trade Technology Pte. Ltd.

Adaptive Biotechnologies Corp

26.49
+0.40001.53%
Post-market: 26.33-0.1600-0.60%19:30 EDT
Volume:1.53M
Turnover:40.27M
Market Cap:4.23B
PE:-64.41
High:26.85
Open:26.11
Low:25.97
Close:26.09
52wk High:30.74
52wk Low:12.00
Shares:159.76M
Float Shares:125.00M
Volume Ratio:0.74
T/O Rate:1.22%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4113
EPS(LYR):-0.3922
ROE:-38.76%
ROA:-4.12%
PB:29.61
PE(LYR):-67.55

Loading ...

Adaptive Biotechnologies Chief Commercial Officer Susan Bobulsky Disposes of 1,299 Common Shares for $31,176

Reuters
·
Aug 04

Veracyte Q2 Revenue Rises on Decipher and Afirma Test Sales

Reuters
·
Jul 31

Fulgent Genetics Q2 Revenue Rises 20% Sequentially, Sees Billing System Transition Delay

Reuters
·
Jul 31

CareDx Q2 Revenue Beats Estimates; Outlook Lifted

Reuters
·
Jul 31

Adaptive Biotechnologies is Maintained at Buy by Guggenheim

Dow Jones
·
Jul 30

Adaptive Biotechnologies price target raised to $25 from $24 at BTIG

TIPRANKS
·
Jul 30

Adaptive Biotechnologies Corp : Morgan Stanley Raises Target Price to $22 from $20

THOMSON REUTERS
·
Jul 30

U.S. Research ROUNDUP-Equinix, Meta, S&P Global

Reuters
·
Jul 30

Adaptive Biotechnologies Corp Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Jul 30

Adaptive Biotechnologies Q2 Net Loss Widens to $39.9 Million; Revenue Rises 22% to $71.6 Million

Reuters
·
Jul 30

Adaptive Biotechnologies Shares Drop 6.9% in Extended Trading After Posting Quarterly Results

THOMSON REUTERS
·
Jul 30

Adaptive Biotechnologies Q2 EPS $(0.25) Misses $(0.14) Estimate, Sales $71.553M Beat $65.886M Estimate

Benzinga Earnings
·
Jul 30

Adaptive Biotechnologies Q2 EPS USD -0.25

Reuters
·
Jul 30

Adaptive Biotechnologies Expects Fy2026 Mrd Revenue $268 Mln-$278 Mln

THOMSON REUTERS
·
Jul 30

Adaptive Biotechnologies Q2 Adjusted Ebitda USD -700 Thousand

THOMSON REUTERS
·
Jul 30

Adaptive Biotechnologies Reports Second Quarter 2026 Financial Results

THOMSON REUTERS
·
Jul 30

Adaptive Biotechnologies CSO Harlan S. Robins Reports Disposal of Common Shares Worth $10.77 Million

Reuters
·
Jul 24

Is Adaptive Biotechnologies (ADPT) Fully Valued As Its Zacks Upgrade Lifts Earnings Hopes?

Simply Wall St.
·
Jul 23

Earning Preview: Adaptive Biotechnologies Corp Q2 revenue is expected to increase by 33.37%, and institutional views are predominantly bullish

Earnings Agent
·
Jul 23

Adaptive Biotechnologies Chief Commercial Officer Susan Bobulsky Disposes of 5,000 Shares for $115,000

Reuters
·
Jul 21